| Kelly Anne Kurnz, CCC-SLP | |
|
489 Devon Park Dr Ste 301, Wayne, PA 19087-1809 | |
| (484) 367-7131 | |
| Not Available |
| Full Name | Kelly Anne Kurnz |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 489 Devon Park Dr Ste 301, Wayne, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255988440 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SL014751 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Anne Kurnz, CCC-SLP 138 W 4th Ave, Conshohocken, PA 19428-1603 Ph: (610) 742-9131 | Kelly Anne Kurnz, CCC-SLP 489 Devon Park Dr Ste 301, Wayne, PA 19087-1809 Ph: (484) 367-7131 |
News Archive
New research into the treatment of Alzheimer's disease using a popular rheumatoid arthritis drug has caused some concern.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, submitted written comments on March 20 to the U.S. Food and Drug Administration (FDA) in response to the agency's request for feedback in association with its February 20, 2015 public workshop entitled, "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests."
Chronic kidney disease (CKD) is a condition commonly encountered in primary health care the world over. However, a new study published in JAMA Network on September 4, 2019, shows that the standard of primary care is quite variable.
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.
› Verified 5 days ago
Danielle S Foster, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 30 West Ave, Wayne, PA 19087 Phone: 610-688-3936 | |
Carly Holden, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 271 Hillcrest Rd, Wayne, PA 19087 Phone: 610-405-8113 | |
Mrs. Tessa Morgan, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 271 Hillcrest Rd, Wayne, PA 19087 Phone: 610-405-8113 | |
Mrs. Sandra Ashley Spuhler, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 489 Devon Park Dr Ste 301, Wayne, PA 19087 Phone: 484-367-7131 | |
Meghan Kathleen Macomber, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 446 Saint Davids Ave, Wayne, PA 19087 Phone: 610-724-2574 | |
Ms. Shelley Slott, CCCSLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 30 West Ave, Wayne, PA 19087 Phone: 610-688-3635 | |
Amanda Dolata, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 489 Devon Park Dr Ste 301, Wayne, PA 19087 Phone: 484-367-7131 |